BioSpace News Archive

BioInvent International AB (“BioInvent”) (OMXS: BINV) today announces that the Board of Directors has resolved to postpone the annual general meeting until May 28, 2020.

Medi-Immune, Ltd., have revealed ProtectivAir®, a breathing device which has proven effective against viral and bacterial pathogens and is expected to be similarly effective against SARS-CoV-2.

AIkido Pharma Incorporated provided an update onto shareholders

The Council of State and Territorial Epidemiologists is pleased to announce the selection of Janet Hamilton, MPH, as new Executive Director, effective March 29, 2020.

AACC commends the U.S. Senate for passing the Coronavirus Aid, Relief, and Economic Security Act yesterday, which will provide vital support to Americans in the midst of the coronavirus outbreak.

APR Applied Pharma Research s.a. (“APR”), the Swiss pharma company leveraging drug delivery technologies to develop innovative products for niche and rare diseases, today announced that the US Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation for the Company’s drug candidate APR-OD031 for the treatment of Phenylketonuria (“PKU”).

Infiniti Research is a leading provider of market intelligence services to businesses around the globe. For over 15 years, Infiniti has been helping companies across industries to identify key market challenges and strategize to meet the changing market demands.

CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced the closing of the offering of 630,500 shares of its common stock at a price of $12.22 per share, for total gross proceeds of approximately $7.7 million

Across the country, in large urban areas as well as small rural communities, EMTs and paramedics are serving on the frontlines of our nation’s war against the COVID-19 pandemic, oftentimes without the necessary supplies and equipment to ensure the safety of their patients and themselves.

In an ongoing series of research conducted by KMK Consulting, Inc. covering Innovation & Customer Value, Allergan and Bausch Health (backed by its Salix division) were ranked as the top companies best poised to deliver therapeutic innovation in the IBS market. T